INZY - Inozyme Pharma appoints Kurt Gunter as Chief Medical Officer

Inozyme Pharma (NASDAQ:INZY) appoints Kurt Gunter, M.D., as chief medical officer.  Dr. Gunter, who most recently served as chief medical officer, cell therapy, and head of regulatory affairs at Athenex. “Kurt’s experience across the entirety of the drug development process will be invaluable as we advance INZ-701 in our ongoing Phase 1/2 clinical trials in patients with ENPP1 Deficiency and ABCC6 Deficiency and prepare for our later-stage studies.” said  Axel Bolte co-founder, president, and CEO

For further details see:

Inozyme Pharma appoints Kurt Gunter as Chief Medical Officer